Literature DB >> 12573613

Global non-viral gene transfer to the primate brain following intravenous administration.

Yun Zhang1, Felix Schlachetzki, William M Pardridge.   

Abstract

Expression plasmids encoding either luciferase or beta-galactosidase were encapsulated in the interior of an "artificial virus" comprised of an 85 nm pegylated immunoliposome, which was targeted to the rhesus monkey brain in vivo with a monoclonal antibody (MAb) to the human insulin receptor (HIR). The HIRMAb enables the liposome carrying the exogenous gene to undergo transcytosis across the blood-brain barrier and endocytosis across the neuronal plasma membrane following intravenous injection. The level of luciferase gene expression in the brain was 50-fold higher in the rhesus monkey as compared to the rat. Widespread neuronal expression of the beta-galactosidase gene in primate brain was demonstrated by both histochemistry and confocal microscopy. This approach makes feasible reversible adult transgenics in 24 hours.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12573613     DOI: 10.1016/s1525-0016(02)00018-7

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  43 in total

1.  Dual-gene, dual-cell type therapy against an excitotoxic insult by bolstering neuroenergetics.

Authors:  Tonya M Bliss; Miranda Ip; Elise Cheng; Masabumi Minami; Luc Pellerin; Pierre Magistretti; Robert M Sapolsky
Journal:  J Neurosci       Date:  2004-07-07       Impact factor: 6.167

Review 2.  Targeted endothelial nanomedicine for common acute pathological conditions.

Authors:  Vladimir V Shuvaev; Jacob S Brenner; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

Review 3.  Drug transport to brain with targeted liposomes.

Authors:  Anita Schnyder; Jörg Huwyler
Journal:  NeuroRx       Date:  2005-01

Review 4.  Drug transport to brain with targeted nanoparticles.

Authors:  Jean-Christophe Olivier
Journal:  NeuroRx       Date:  2005-01

Review 5.  The blood-brain barrier: bottleneck in brain drug development.

Authors:  William M Pardridge
Journal:  NeuroRx       Date:  2005-01

Review 6.  shRNA and siRNA delivery to the brain.

Authors:  William M Pardridge
Journal:  Adv Drug Deliv Rev       Date:  2007-03-16       Impact factor: 15.470

Review 7.  Blood-brain barrier transport of therapeutics via receptor-mediation.

Authors:  Angela R Jones; Eric V Shusta
Journal:  Pharm Res       Date:  2007-07-10       Impact factor: 4.200

Review 8.  RNA interference and nonviral targeted gene therapy of experimental brain cancer.

Authors:  Ruben J Boado
Journal:  NeuroRx       Date:  2005-01

Review 9.  Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy.

Authors:  William M Pardridge
Journal:  NeuroRx       Date:  2005-01

Review 10.  Targeting anti-HIV drugs to the CNS.

Authors:  Kavitha S Rao; Anuja Ghorpade; Vinod Labhasetwar
Journal:  Expert Opin Drug Deliv       Date:  2009-08       Impact factor: 6.648

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.